Amendment No. 1 to the Exclusive License Agreement

Exhibit 10.12B

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Amendment No. 1

to the

Exclusive License Agreement

This Amendment No. 1, dated as of August 4, 2014, is entered into between Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute, a Washington non-profit corporation (“Licensor”) and Juno Therapeutics, Inc., a Delaware corporation (“Licensee”)

 

•

Licensor and Licensee previously entered into an Exclusive License Agreement, dated as of February 13, 2014 (“Original Agreement”).

 

•

Licensor and Licensee want to amend the Original Agreement to add patent application(s) to the Licensed Patents, all as set forth below.

Accordingly, the parties agree as follows:

1. Exhibit A. Exhibit A is hereby amended to add the following patent application(s):

 

[***]		[***]		[***]
[***]		[***]		[***]
[***]		[***]		[***]

2. Exhibit A Restated. Exhibit A, in full, now reads as follows:

 

[***]		[***]		[***]
[***]		[***]		[***]
[***]		[***]		[***]
[***]		[***]		[***]
[***]		[***]		[***]
[***]		[***]		[***]

3. Full Force and Effect. Except as modified by this Amendment No. 1, all other terms of the Original Agreement will remain in full force and effect.

---

Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute and Juno Therapeutics, Inc., Exclusive License Agreement, Amendment 1, Page 2 of 2

 

 

 

 

JUNO THERAPEUTICS, INC.						SEATTLE CHILDREN’S HOSPITAL D/B/A SEATTLE CHILDREN’S RESEARCH INSTITUTE
By:		/s/ ▇. ▇▇▇▇▇▇				By:		/s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, PhD
Name:		▇. ▇▇▇▇▇▇				Name:		▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, PhD
Title:		C.E.O.				Title:		President, Seattle Children’s Research Institute

 

2